Triage System Gets High Marks for Ovarian Cancer Debulking Surgery Key factors predicted threefold higher risk of 90-day mortality with primary surgery Mar 26, 2021
HIPEC Combo Doubles PFS in Advanced Ovarian Cancer Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study Mar 26, 2021
Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer Ixabepilone plus bevacizumab yielded responses in a third of patients Mar 26, 2021
Vaccines and Rare Clotting Disorders: What's the Link? Causal relation appears possible, but evidence still indicates it's extremely rare Mar 25, 2021
Model: Give COVID-19 Vaccine to All Patients Before Surgery Prioritizing surgical patient population could avert more COVID deaths Mar 25, 2021
Marrow Cell Stimulator to Treat Alzheimer's Disease? Unusual approach pans out in mid-stage trial Mar 24, 2021
Op-Ed: Blood Cancer Patients Need More COVID Vax Answers Patients are left wondering, "will I be protected?" Mar 24, 2021
Safety Reassurance for Major Class of Diabetes Drugs Pooled trial data show no link to breast cancer Mar 24, 2021
Little Benefit With Adjuvant Therapy for High-Risk Endometrial Cancer Chemo prevented relapse but did not improve survival, no benefit from radiotherapy Mar 23, 2021
Androgen Receptor Inhibitor Active in Endometrial Cancer SGO: Apatinib for platinum-resistant ovarian cancer, pembrolizumab for advanced vulvar cancer Mar 22, 2021
Hormonal IUD Shows Promise in Early Endometrial Cancer Regression seen in 82% of women with precancerous lesions Mar 21, 2021
Small Molecule Inhibitor Shows Promise in Resistant Ovarian Cancer Responses in 37% of patients with AVB-500, higher without prior bevacizumab Mar 21, 2021
Op-Ed: Primary Care and Specialty Ping Pong Let's put an end to bureaucratic medicine and treat the patient in front of us Mar 21, 2021
Is MIS Viable for Interval Debulking in Ovarian Cancer? Retrospective study compared approach versus open surgery after neoadjuvant chemotherapy Mar 21, 2021
PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancer Modest improvement in PFS with rucaparib but worse outcome for reversion mutation Mar 20, 2021
Practice-Changing Trial in Second-Line Endometrial Cancer Pembrolizumab plus lenvatinib improved median OS by nearly 7 months versus chemotherapy Mar 19, 2021
Class of Cancer Drug Linked to Aneurysms, Artery Dissections Database analysis finds more reports than expected with antiangiogenic drugs Mar 18, 2021
Acupuncture Tops Usual Care for Pain in Cancer Survivors Two types of acupuncture proved superior, with one better than the other Mar 18, 2021
C3 Inhibitor Prevails in Trial of Rare Hemoglobinuria Improvement in hemoglobin, transfusion independence with pegcetacoplan for PNH Mar 17, 2021
Time to Revisit Distant Nodal Status in Breast Cancer Curability? Comparable survival for distant and regional nodal involvement, when treated similarly Mar 16, 2021
Holding tPA for All DOAC Users Not the Way to Go, Stroke Docs Say Clinical conundrum could be solved by a point-of-care DOAC test Mar 15, 2021
Whole-Genome Sequencing Makes a Case in Leukemia Study More actionable alterations detected in myeloid malignancies versus cytogenetics Mar 10, 2021
Study Confirms Risk-Adapted CRS Prophylaxis for Acute Leukemia Tocilizumab reduced severe cytokine release syndrome in children, young adults Mar 09, 2021
New Guideline Lowers Age to Begin Colorectal Cancer Screening Update comes as incidence has doubled in people under 50 Mar 09, 2021
USPSTF Expands Lung Cancer Screening Criteria Lower age for starting, new definition of 'heavy smoker' double eligibility for screening Mar 09, 2021
PD-1 Inhibitor Falls Short in Triple-Negative Breast Cancer No survival benefit with pembrolizumab vs chemotherapy in second-, third-line treatment Mar 08, 2021
Entrectinib Impresses in Certain Lung Cancers Durable responses in most patients with advanced NSCLC, active in brain mets Mar 05, 2021
New Targeted Therapies Show Promise in Cancer Selected abstracts from the ESMO Targeted Anticancer Therapies virtual meeting Mar 03, 2021
Mammo Study: One Saves Lives, More Exams Save More Lives Risk of fatal breast cancer decreases with increasing participation in screening Mar 02, 2021
Neoadjuvant Dual ICI Leads to Clinical Benefit in Operable NSCLC More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab. Feb 18, 2021
A CLEAR Upfront Winner in Advanced RCC? Pembrolizumab-lenvatinib makes splash with longest PFS benefit in RCC recorded to date Feb 14, 2021
Practice-Changing Trial in Metastatic Papillary RCC Cabozantinib improved PFS, response rates over sunitinib Feb 14, 2021
New Standard in High-Risk Muscle-Invasive Bladder Cancer? Adjuvant nivolumab improves DFS in all comers, PD-L1 population Feb 13, 2021
New Drug OK'd for Chemo-Induced Myelosuppression in SCLC CDK4/6 inhibitor cut the risk for severe neutropenia in small-cell lung cancer patients Feb 13, 2021
CCR Score Could Offer ADT-Free Path in Higher-Risk Prostate Cancer Large proportion of intermediate- to high-risk patients could avoid aggressive therapy Feb 12, 2021
Survival Boost in Bladder Cancer With Antibody-Drug Conjugate Four-month absolute improvement with enfortumab vedotin in previously treated disease Feb 12, 2021
Radionuclide Tx Wins in Third-Line Metastatic CRPC Early trial shows improved PFS, response rates versus cabazitaxel Feb 11, 2021
Hit and Miss in Castration-Resistant Prostate Cancer No OS benefit with apalutamide-abiraterone, despite improved PFS Feb 11, 2021
Want Data on Recently Approved Actinic Keratosis Drug? Here You Go Phase III trial now published in full for topical anti-proliferative treatment Feb 10, 2021